Financial Performance - Revenue for Q3 2024 reached ¥106,997,011.86, an increase of 20.02% compared to the same period last year[2] - Net profit attributable to shareholders was -¥874,456.04, a decrease of 123.91% year-on-year[2] - Net profit excluding non-recurring items was -¥2,374,938.89, a significant decline of 2,132.47% compared to the previous year[2] - The company reported a 56.34% decrease in revenue for the first nine months of 2024, totaling ¥325,753,716.96, primarily due to reduced sales of raw materials[6] - Total operating revenue for Q3 2024 was CNY 325,753,716.96, a decrease of 56.4% compared to CNY 746,127,863.80 in the same period last year[17] - The company reported a net loss of CNY 7,148,791.12 for Q3 2024, compared to a profit of CNY 381,896,140.21 in Q3 2023[17] - The net profit for Q3 2024 was -2,653,779.13 CNY, compared to a net profit of 313,190,833.52 CNY in the same period last year, indicating a significant decline[18] - Basic and diluted earnings per share for Q3 2024 were both -0.02 CNY, down from 2.49 CNY in the previous year[19] - The total profit (loss) for Q3 2024 was -10,897,164.57 CNY, compared to a profit of 379,615,109.46 CNY in the same period last year[18] - The company’s total comprehensive income for Q3 2024 was -2,653,779.13 CNY, compared to 313,190,833.52 CNY in the same period last year[18] Assets and Liabilities - Total assets as of September 30, 2024, amounted to ¥1,746,589,677.85, down 5.02% from the end of the previous year[2] - Non-current assets totaled CNY 1,048,271,915.68, an increase from CNY 1,016,824,783.44 at the beginning of the period, reflecting a growth of 3.1%[14] - Total liabilities decreased to CNY 177,607,713.38 from CNY 235,722,693.38, a decline of 24.6%[15] - The company’s total assets were CNY 1,746,589,677.85, down from CNY 1,838,994,561.98, a decrease of 5.0%[15] Cash Flow - Cash flow from operating activities for the year-to-date was ¥109,128,879.30, an increase of 107.50%[2] - Cash received from sales and services decreased by 37.41% to approximately 514.41 million in the same period last year[8] - Cash received from other operating activities dropped by 84.25% to approximately 75.05 million in the previous year[8] - Cash recovered from investments fell by 62.75% to approximately 1.24 billion in the previous year[8] - Cash paid for fixed assets and intangible assets decreased by 66.21% to approximately 169.40 million last year[8] - Cash paid for investments decreased by 59.86% to approximately 1.05 billion in the previous year[8] - Cash paid for dividends and interest decreased by 37.60% to approximately 50.70 million last year[8] - Cash and cash equivalents increased by 39.63% to ¥207,432,231.98, attributed to improved operating cash flow[5] - Cash and cash equivalents increased to CNY 207,432,231.98 as of September 30, 2024, up from CNY 148,553,750.34 at the beginning of the period, representing a growth of 39.4%[13] - Cash and cash equivalents at the end of Q3 2024 totaled 194,291,924.17 CNY, down from 288,778,223.22 CNY at the end of the previous year[20] Shareholder Information - The total number of common shareholders at the end of the reporting period was 21,626, with no preferred shareholders[9] - The largest shareholder, Yang Xining, holds 27.23% of the shares, amounting to 34,455,650 shares[9] - The company plans to unlock 25% of the locked shares annually for key management personnel, with the first release scheduled for October 26, 2024[11] Operating Costs and Expenses - The company experienced a 70.72% increase in operating expenses, totaling ¥3,896,564.18, primarily due to increased charitable donations[7] - Total operating costs for Q3 2024 were CNY 349,459,875.73, down from CNY 366,447,775.50 in Q3 2023, reflecting a reduction of 4.3%[17] Future Plans - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[16]
拓新药业(301089) - 2024 Q3 - 季度财报